This panel utilizes FDA-cleared assays following the modified 2-tier testing (MTTT) algorithm to aid in the diagnosis of Lyme disease in individuals with clinical signs and symptoms consistent with Lyme disease. Lyme disease should be considered based on the presence of typical signs and symptoms of infection in patients with a history of possible exposure to infected ticks.